Q2 FY2026 EarningsQ2 FY26 beat consensus across all major profitability metrics: revenue reached $36.9M (+1.6% vs. $36.4M consensus), while GAAP EPS of $0.15 exceeded the $0.105 expectation. Gross margin improved to 58.0%, surpassing the 57.4% consensus by 0.57pct. The Patient Services segment drove the top-line beat with 15.2% YoY growth, offsetting a 16.1% revenue decline in Device Solutions following a major contract restructuring.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Infusystem(INFU) the Revenue is 36.93 M (+2.59%), Beat estimate;the EBIT is 4.152 M (+9.93%), Beat estimate;the EPS is 0.15 (+25%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.04B2.59%
0.04B0.97%
+0.00B1.62%
EBITExceed expectations
0.00B9.93%
0.00B11.95%
+0.00B21.88%
EPSExceed expectations
0.1525.00%
0.10512.50%
+0.045037.50%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf